Adipocytes are one of the primary stromal cells in many tissues, and they are considered to
play an active role in the tumor microenvironment. Cancer-associated adipocytes (CAAs) …

Investigators are using checkpoint inhibitors (CPIs) to treat aggressive hematologic
malignancies in patients undergoing allogeneic hematopoietic stem cell transplantation (allo …

Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …

Background Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade≥ 2
immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear …

Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …

PD-1 blockade is an effective therapy in relapsed/refractory (R/R) classical Hodgkin
Lymphoma (cHL) who have relapsed after or are ineligible for autologous hematopoietic cell …

Immunotherapy has expanded the therapeutic landscape for advanced cancers, including
solid tumors and lymphomas. For many patients with cancer, these agents have been shown …

Although classical Hodgkin lymphoma (cHL) is usually curable, 20–30% of the patients
experience treatment failure and most of them are typically treated with salvage …

Although the survival rate of hematological malignancies (HM) has increased in recent
years, the unnecessary adverse effect to the body is usually generated by the traditional …

Introduction Long-term efficacy of anti-PD1 therapy and the need for a consolidation with
allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients …